Filing Details

Accession Number:
0001179110-13-006105
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-04-01 19:36:43
Reporting Period:
2013-03-28
Filing Date:
2013-04-01
Accepted Time:
2013-04-01 19:36:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1012140 Onyx Pharmaceuticals Inc ONXX Biological Products, (No Disgnostic Substances) (2836) 943154463
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1197018 Anthony N Coles C/O Onyx Pharmaceuticals, Inc.
249 E. Grand Ave.
South San Francisco CA 94080
Chairman & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-03-28 10,938 $35.18 119,392 No 4 M Direct
Common Stock Disposition 2013-03-28 10,938 $90.00 108,454 No 4 S Direct
Common Stock Acquisiton 2013-03-28 26,800 $0.00 135,254 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2013-03-28 10,938 $0.00 10,938 $35.18
Common Stock Stock Option (Right to Buy) Acquisiton 2013-03-28 75,300 $0.00 75,300 $88.86
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
54,687 2021-03-31 No 4 M Direct
75,300 2023-03-27 No 4 A Direct
Footnotes
  1. Shares sold pursuant to a 10b5-1 Plan.
  2. Represents restricted stock units granted to the reporting person. Each restricted stock unit represents a right to receive one share of the issuer's common stock. The restricted stock units vest annually over four years.
  3. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting of 48 months.
  4. Includes shares purchased through the issuer's ESPP.